Literature DB >> 33283260

Bone status in adolescents and young adults with type 1 diabetes: a 10-year longitudinal study.

Agata Chobot1, Oliwia Janota2, Katarzyna Bak-Drabik3, Joanna Polanska4, Wojciech Pluskiewicz5.   

Abstract

INTRODUCTION: This study presents a 10-years longitudinal assessment of bone status in adolescents and young adults with type 1 diabetes (T1D).
MATERIALS AND METHODS: Thirty two patients (12 female, aged 20.5±3.93 years, T1D duration 13.9±1.97 years) were studied using Quantitative Ultrasound (QUS) and Dual Energy X-ray Absorptiometry (DXA). Standard deviation scores (SDS) for these results were calculated. Following clinical parameters were analyzed: sex, age, T1D duration, anthropometric parameters, daily insulin requirement (DIR), mean of glycated hemoglobin (HbA1c) in the year preceding the examination, medication other than insulin, history of bone fractures and comorbidities.
RESULTS: The current and past (measured 10 years earlier) QUS results did not differ and showed a significant correlation (r=0.55, p=0.001). We found no relation of QUS results and anthropometric parameters or gender. DXA parameters did not correlate with the present QUS measurement. DXA and QUS results were independent from HbA1c, co-morbidities or additional medicaments intake.
CONCLUSIONS: Bone status parameters of the examined patients with currently suboptimal glycemic control were found to be lowered in comparison to normative reference population, both at baseline and follow-up, although no further deterioration was observed during the 10-year follow-up period.

Entities:  

Keywords:  bone status; dual X-ray absorptiometry; glycemic control; quantitative ultrasound; type 1 diabetes

Year:  2020        PMID: 33283260     DOI: 10.5603/EP.a2020.0080

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  1 in total

Review 1.  Glycemic Control and Bone in Diabetes.

Authors:  David R Weber; Fanxin Long; Babette S Zemel; Joseph M Kindler
Journal:  Curr Osteoporos Rep       Date:  2022-10-10       Impact factor: 5.163

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.